Leslie J Williams is a biopharmaceutical industry veteran. As a serial entrepreneur, an experienced biotech CEO and board of directors’ member, she has proven expertise in building companies, raising funds, and negotiating strategic collaborations both domestically and internationally. Leslie is founding CEO, President & Director of hC Bioscience, Inc. a pioneer, innovator and leader in protein editing with tRNA based therapeutics targeting genetically defined diseases including cancer. She serves on the Board of Directors for the Biotechnology Innovation Organization (BIO), Make-A-Wish Massachusetts & Rhode Island, Ocular Therapeutix (Nasdaq: OCUL), and), CSCRI (Coral Sea Clinical Research Institute) and the Board of Advisors of Life Science Cares. In addition, she serves on the Editorial Advisory Board of Life Science Leader, is a founding Ambassador of BioBoost and serves as a mentor at the GLG Institute. She is an EIR at University of Iowa and University of Virginia and is an Operating Partner at Accelerator Life Science Partners. Ms. Williams was formerly Founder, Director, President and CEO at ImmusanT developing immunotherapies for autoimmune diseases until the reverse merger in 2019. Prior to that she was President & CEO at Ventaira Pharmaceuticals developing therapies using the lung as a portal for delivery until it was sold the end of 2007. Williams was a founding member of the INO Therapeutics team developing a treatment for pulmonary hypertension in newborns. She has prior pharmaceutical experience at Merck and GSK, and drug-delivery and monitoring experience at Datex Ohmeda. She was a venture partner at Battelle Ventures where she sourced and evaluated deals. Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree from the University of Iowa. Before entering industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa.